[1] 汪建平. 中低位直肠癌诊治现状及展望[J]. 中国实用外科杂志,2009,29(4):287-290. DOI:10.3321/j.issn:1005-2208.2009.04.003.
[2] van Gijn W, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial [J]. Lancet Oncol, 2011, 12(6): 575-582. DOI: 10.1016/S1470-2045(11)70097-3.
[3] Hong YS, Kim SY, Lee JS, et al. Oxaliplatin-based adjuvant chemotherapy for rectal cancer after preoperative chemoradiotherapy (ADORE): long-term results of a randomized controlled trial [J]. J Clin Oncol, 2019, 37(33): 3111-3123. DOI: 10.1200/JCO.19.00016.
[4] Bahadoer RR, Dijkstra EA, van Etten B, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial [J]. Lancet Oncol, 2021, 22(1): 29-42. DOI: 10.1016/S1470-2045(20)30555-6.
[5] Rödel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer [J]. J Clin Oncol, 2005, 23(34): 8688-8696. DOI: 10.1200/JCO.2005.02.1329.
[6] 中华人民共和国国家卫生健康委员会. 中国结直肠癌诊疗规范(2020年版)[J]. 中华外科杂志,2020,58(8):561-585. DOI:10.3760/cma.j.cn112139-20200518-00390.
[7] Beddy D, Hyland JM, Winter DC, et al. A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy [J]. Ann Surg Oncol, 2008, 15(12): 3471-3477. DOI: 10.1245/s10434-008-0149-y.
[8] Jacobs L, Intven M, van Lelyveld N, et al. Diffusion-weighted MRI for early prediction of treatment response on preoperative chemoradiotherapy for patients with locally advanced rectal cancer: a feasibility study [J]. Ann Surg, 2016, 263(3): 522-528. DOI: 10.1097/SLA.0000000000001311.
[9] Nie K, Shi L, Chen Q, et al. Rectal cancer: assessment of neoadjuvant chemoradiation outcome based on radiomics of multiparametric MRI [J]. Clin Cancer Res, 2016, 22(21): 5256-5264. DOI: 10.1158/1078-0432.CCR-15-2997.
[10] Zhu HB, Zhang XY, Zhou XH, et al. Assessment of pathological complete response to preoperative chemoradiotherapy by means of multiple mathematical models of diffusion-weighted MRI in locally advanced rectal cancer: a prospective single-center study [J]. J Magn Reson Imaging, 2017, 46(1): 175-183. DOI: 10.1002/jmri.25567.
[11] Kim IJ, Lim SB, Kang HC, et al. Microarray gene expression profiling for predicting complete response to preoperative chemoradiotherapy in patients with advanced rectal cancer [J]. Dis Colon Rectum, 2007, 50(9): 1342-1353. DOI: 10.1007/s10350-007-277-7.
[12] Hur H, Tulina I, Cho MS, et al. Biomarker-Based scoring system for prediction of tumor response after preoperative chemoradiotherapy in rectal cancer by reverse transcriptase polymerase chain reaction analysis [J]. Dis Colon Rectum, 2016, 59(12): 1174-1182. DOI: 10.1097/DCR.0000000000000711.
[13] Watanabe T, Kobunai T, Akiyoshi T, et al. Prediction of response to preoperative chemoradiotherapy in rectal cancer by using reverse transcriptase polymerase chain reaction analysis of four genes [J]. Dis Colon Rectum, 2014, 57(1): 23-31. DOI: 10.1097/01.dcr.0000437688. 33795.9d.
[14] Yu J, Li N, Wang X, et al. Circulating serum microRNA-345 correlates with unfavorable pathological response to preoperative chemoradiotherapy in locally advanced rectal cancer [J]. Oncotarget, 2016, 7(39): 64233-64243. DOI: 10.18632/oncotarget.11649.
[15] 孙艳武,池畔,徐本华,等. 直肠癌新辅助放化疗后病理完全缓解预测因素分析[J]. 中华胃肠外科杂志,2014(6):556-560. DOI:10.3760/cma.j.issn.1671-0274. 2014.06.009.
[16] Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs [J]. Cell, 2009, 136(4): 629-641. DOI: 10.1016/j.cell.2009.02.006.
[17] Batista PJ, Chang HY. Long noncoding RNAs: cellular address codes in development and disease [J]. Cell, 2013, 152(6): 1298-307. DOI: 10.1016/j.cell.2013.02.012.
[18] Zhao R, Zhang Y, Zhang X, et al. Exosomal long noncoding RNA HOTTIP as potential novel diagnostic and prognostic biomarker test for gastric cancer [J]. Mol Cancer, 2018, 17(1): 68. DOI: 10.1186/s12943-018-0817-x.
[19] Lu R, Zhang J, Zhang W, et al. Circulating HOTAIR expression predicts the clinical response to neoadjuvant chemotherapy in patients with breast cancer [J]. Cancer Biomark, 2018, 22(2): 249-256. DOI: 10.3233/CBM-170874.
[20] Tan SK, Pastori C, Penas C, et al. Serum long noncoding RNA HOTAIR as a novel diagnostic and prognostic biomarker in glioblastoma multiforme [J]. Mol Cancer, 2018, 17(1): 74. DOI: 10.1186/s12943-018-0822-0.
[21] Xie Y, Zhang Y, Du L, et al. Circulating long noncoding RNA act as potential novel biomarkers for diagnosis and prognosis of non-small cell lung cancer [J]. Mol Oncol, 2018, 12(5): 648-658. DOI: 10.1002/1878-0261.12188.
[22] Wang Y, Liu XJ, Yao XD. Function of PCA3 in prostate tissue and clinical research progress on developing a PCA3 score [J]. Chin J Cancer Res, 2014, 26(4): 493-500. DOI: 10.3978/j.issn.1000-9604.2014.08.08.
|